Lercheconner6655
The phylogenetic relationship is strongly supported by ultrafast bootstrap values for the maximum-likelihood trees of both genetic markers (16S, 96; COI, 100, Figure 1A). Bayesian analysis of the concatenated sequences resulted in a tree with similar topology and high posterior probability support (0.99; Supplementary Figure S1). In addition, haplotype networks inferred from COI and 16S (Supplementary Figure S2) showed a well-separated clade containing the new species (two for COI, four for 16S). The number of mutational steps between haplotypes for the new species samples is very low (1-4 in 16S; one in COI), and the minimum number of mutational steps from the nearest species is nine for 16S (distance to A. certus) and 28 for COI (distance to A. glyphus).Despite 250 years of taxonomic classification and over 1.2 million species already catalogued, known species diversity is only a small part of true species diversity on Earth, and thus, the known species are only the tip of iceberg. Here, we investigated the genus Pholcus Walckenaer, 1805 of the family Pholcidae C. L. Koch, 1850 in the Changbai Mountains, Northeast China, which provides an excellent case of high species diversity. Previously, only 14 endemic Pholcus spiders, all belonging to the P. phungiformes species group, and two introduced species P. manueli Gertsch, 1937 and P. zichyi Kulczyński, 1901 from the P. crypticolens species group, have been recorded from this area. Dulaglutide clinical trial Our study confirmed 11 new species of the P. phungiformes species group based on morphology and three methods of molecular species delimitation P. gaizhou Yao & Li, sp. nov., P. guanshui Yao & Li, sp. nov., P. jiguanshan Yao & Li, sp. nov., P. longxigu Yao & Li, sp. nov., P. luoquanbei Yao & Li, sp. nov., P. shenshi Yao & Li, sp. nov., P. tianmenshan Yao & Li, sp. nov., P. wangjiang Yao & Li, sp. nov., P. link2 xingqi Yao & Li, sp. nov., P. yaoshan Yao & Li, sp. nov., and P. yuhuangshan Yao & Li, sp. nov. This study brings the fauna of the P. phungiformes species group from the Changbai Mountains to 25 species, approximately two times more than previously known, which could indicate that species diversity in the area is underestimated for all arthropod fauna.Platelets are produced by hematopoietic stem cells via megakaryocytes in the bone marrow and play a critical role in hemostasis. The aim of this study was to develop a new platelet model based on the thrombopoiesis and platelet life-cycle by a quantitative systems pharmacology modeling approach, which could describe changes in platelet count profiles in platelet-related diseases and drug intervention. The proposed platelet model consists of 44 components. The model was applied to thrombopoiesis of a thrombopoietin receptor agonist, lusutrombopag. It could well describe the observed platelet count profiles after administration of lusutrombopag for both healthy subjects and patients with chronic liver disease and thrombocytopenia. This model should be useful for understanding the disease progression of platelet-related conditions, such as thrombocytopenia and for predicting platelet count profiles in various disease situations related to platelets and drug administration in drug development.The chromatin-based DNA damage response pathway is tightly orchestrated by histone post-translational modifications, including histone H2A ubiquitination. Ubiquitination plays an integral role in regulating cellular processes including DNA damage signaling and repair. The ubiquitin E3 ligase RNF168 is essential in assembling a cohort of DNA repair proteins at the damaged chromatin via its enzymatic activity. RNF168 ubiquitinates histone H2A(X) at the N terminus and generates a specific docking scaffold for ubiquitin-binding motif-containing proteins. The regulation of RNF168 at damaged chromatin and the mechanistic implication in the recruitment of DNA repair proteins to the damaged sites remain an area of active investigation. Here, we review the function and regulation of RNF168 in the context of ubiquitin-mediated DNA damage signaling and repair. We will also discuss the unanswered questions that require further investigation and how understanding RNF168 targeting specificity could benefit the therapeutic development for cancer treatment.
To investigate the mechanism of action of N-acetylcysteine (NAC) in depressive symptoms in young individuals at familial risk for bipolar disorder.
We conducted an 8-week open label clinical trial of NAC 2400 mg/days in 15-24 years old depressed offspring of a bipolar I disorder parent, with baseline and endpoint proton magnetic resonance spectroscopy acquired within the left ventrolateral prefrontal cortex (VLPFC).
Nine participants were enrolled and finished the study. NAC significantly improved depressive and anxiety symptom scores, and clinical global impression (all p < .001). There was a non-significant reduction in glutamate levels in the left VLPFC. Reduction in depressive symptom scores was positively associated with reduction in glutamate levels in the left VLPFC (p = .007).
This pilot study suggests that NAC might be efficacious for depressive symptoms in at-risk youth, and that its mechanism of action involves the modulation of glutamate in the left VLPFC.
This pilot study suggests that NAC might be efficacious for depressive symptoms in at-risk youth, and that its mechanism of action involves the modulation of glutamate in the left VLPFC.
Pathogenic variants in the L-type Ca
channel gene CACNA1C cause a multi-system disorder that includes severe long QT syndrome (LQTS), congenital heart disease, dysmorphic facial features, syndactyly, abnormal immune function, and neuropsychiatric disorders, collectively known as Timothy syndrome. In 2015, a variant in CACNA1C (p.R518C) was reported to cause cardiac-only Timothy syndrome, a genetic disorder with a mixed phenotype of congenital heart disease, hypertrophic cardiomyopathy (HCM), and LQTS that lacked extra-cardiac features. We have identified a family harboring the p.R518C pathogenic variant with a wider spectrum of clinical manifestations.
A four-generation family harboring the p.R518C pathogenic variant was reviewed in detail. The proband and his paternal great-uncle underwent comprehensive cardiac gene panel testing, and his remaining family members underwent cascade testing for the p.R518C pathogenic variant.
In addition to displaying cardinal features of CACNA1C disorders including LQTS, congenital heart disease, HCM, and sudden cardiac death, family members manifested atrial fibrillation and sick sinus syndrome.
Our report expands the cardiac phenotype of CACNA1C variants and reflects the variable expressivity of mutations in the L-type Ca
channel.
Our report expands the cardiac phenotype of CACNA1C variants and reflects the variable expressivity of mutations in the L-type Ca2+ channel.So far, the practical application of Li metal batteries has been hindered by the undesirable formation of Li dendrites and low Coulombic efficiencies (CEs). link3 Herein, 1,2-diethoxyethane (DEE) is proposed as a new electrolytic solvent for lithium metal batteries (LMBs), and the performances of 1.0 m LiFSI in DEE are evaluated. Because of the low dielectric constant and dipole moment of DEE, the majority of the FSI- exists in associated states like contact ion pairs and aggregates, which is similar to the highly concentrated electrolytes. These associated complexes are involved in the reduction reaction on the Li metal anode, forming sound solid electrolyte interphase layers. Furthermore, free FSI- ions in DEE are observed to participate in the formation of cathode electrolyte interphase layers. These passivation layers not only suppress dendrite growth on the Li anode but also prevent unwanted side-reactions on the LiFePO4 cathode. The average CE of the Li||Cu cells in LiFSI-DEE is observed to be 98.0%. Moreover, LiFSI-DEE also plays an important role in enhancing the cycling stability of the Li||LiFP cell with a capacity retention of 93.5% after 200 cycles. These results demonstrate the benefits of LiFSI-DEE, which creates new possibilities for high-energy-density rechargeable LMBs.3D carbon-based materials with multiscale hierarchy are promising electrode materials for electrochemical energy storage and conversion applications, but the synthesis in an efficient and large-scale way is still a great challenge. Herein, a carbon nanorod-assembled 3D superstructure is facilely fabricated by morphology-preserving conversion of a metal-organic framework (MOF) nanorod-assembled superstructure. The MOF superstructure can be fabricated in one-pot synthesis with high reproducibility and high yield by precise control of the MOF nucleation and growth. Its derived carbon inherits the nanorod-assembled superstructure and possesses abundant micropores and nitrogen doping, which can serve as a high-performance anode material for fast potassium storage. The superiority of the superstructure and the synergism of micropore capturing and nitrogen anchoring are verified both experimentally and theoretically.Myocardial infarction requires urgent reperfusion to salvage viable heart tissue. However, reperfusion increases infarct size further by promoting mitochondrial damage in cardiomyocytes. Exosomes from a wide range of different cell sources have been shown to activate cardioprotective pathways in cardiomyocytes, thereby reducing infarct size. Yet, it is currently challenging to obtain highly pure exosomes in quantities enough for clinical studies. To overcome this problem, we used exosomes isolated from CTX0E03 neuronal stem cells, which are genetically stable, conditionally inducible and can be produced on an industrial scale. However, it is unknown whether exosomes from neuronal stem cells may reduce cardiac ischaemia/reperfusion injury. In this study, we demonstrate that exosomes from differentiating CTX0E03 cells can reduce infarct size in mice. In an in vitro assay, these exosomes delayed cardiomyocyte mitochondrial permeability transition pore opening, which is responsible for cardiomyocyte death after reperfusion. The mechanism of MPTP inhibition was via gp130 signalling and the downstream JAK/STAT pathway. Our results support previous findings that exosomes from non-cardiomyocyte-related cells produce exosomes capable of protecting cardiomyocytes from myocardial infarction. We anticipate our findings may encourage scientists to use exosomes obtained from reproducible clinical-grade stocks of cells for their ischaemia/reperfusion studies.
Intraoperative electron radiotherapy (IOERT) followed by hypofractionated whole breast irradiation (HWBI) provides the shortest possible time of adjuvant breast irradiation. The efficacy of either method has been described in previous reports; however, to our knowledge, the efficacy of combined therapy has not been reported.
To compare the toxicity and cosmetic outcome of IOERT as a tumor bed boost followed by HWBI with conventional whole breast irradiation (CWBI) followed by external electron tumor bed boost (EETBB) after breast conserving surgery (BCS) in patients with invasive breast cancer.
In 2019, a prospective noninferiority trial (IRCT20180919041070N2) was started. After BCS, early-stage breast cancer patients were treated by IOERT (10 Gy) and HWBI (42.56 Gy in 16 fractions) or CWBI (50 Gy in 25 fraction) and EETBB (10 Gy in 5) in a double-arm design. Acute/late toxicity and cosmetic outcome were evaluated by common toxicity criteria (CTC) after 1-year follow-up (FUP) at the level of p < .05.